FGF21 Pretreatment Promotes the Cardioprotective Effects of Mesenchymal Stem Cells in Myocardial Infarction via Enhancement of Their Survival and Paracrine Effects
Background: The poor engraftment of mesenchymal stem cells (MSCs) in the ischemic heart post transplantation heavily restricts their cardioprotective benefits in myocardial infarction (MI). Pretreatment has emerged as a novel approach to enhance the biological properties of MSCs and enhance their therapeutic efficacy....